Lonza Group AG operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Lonza Group AG with three other
pharmaceutical manufacturers in Europe:
sales of 241.48 billion Russian Rubles [US$4.26 billion]
of which 81%
Stada Arzneimittel AG
(2.14 billion Euro [US$2.40 billion]
of which 60%
was Generics), and
based in Belgium
(4.18 billion Euro [US$4.69 billion]
of which 100%
During the year ended December of 2016, sales at
Lonza Group AG were 4.13 billion Swiss Francs (US$4.25 billion).
increase of 8.7%
versus 2015, when the company's sales were 3.80 billion Swiss Francs.
This was the third consecutive year of growth at Lonza Group AG.
Sales of Pharma&biotech saw an increase
15.9% in 2016, from
1.60 billion Swiss Francs to 1.85 billion Swiss Francs.
Not all segments of Lonza Group AG experienced an increase in sales in 2016:
sales of Eliminations fell 17.5% to 33.00 million Swiss Francs.
(However, this segment's sales were only a very small portion of the company's overall sales).